Cardinal Health (NYSE: CAH) is scheduled to release its next earnings report on Tuesday, August 12, 2025, before the market opens. This upcoming report will cover the fiscal quarter ending June 2025 (Q4 FY2025) and is a crucial event for investors and analysts to assess the company's financial health, operational performance, and future outlook.

Key Information

Cardinal Health (NYSE: CAH) is set to announce its fourth-quarter and full-year fiscal 2025 results on Tuesday, August 12, 2025. The report will be released before the market opens, typically followed by a conference call to discuss the results with investors and analysts. For this upcoming report, analysts are forecasting an earnings per share (EPS) of $2.03.

Context and Background

Cardinal Health operates as a global integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices worldwide. Its business is primarily divided into two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution (GMPD).

Historical Context

Cardinal Health typically reports its earnings quarterly, aligning with its fiscal year which ends in June. Historically, the fourth-quarter and full-year results are announced in mid-August. For instance, their Q4 FY2024 earnings were reported on August 14, 2024, and Q3 FY2025 earnings were released on May 1, 2025. This consistent schedule allows stakeholders to anticipate and prepare for the financial disclosures.

Recent Performance and Trends

The company has demonstrated robust financial performance in recent quarters. In Q3 Fiscal Year 2025, reported on May 1, 2025, Cardinal Health showcased strong results:

• Operating earnings increased by 21%, and EPS rose by 13% year-over-year, reaching $2.35 per share, surpassing analyst estimates.
• Revenue was nearly $55 billion, flat on a reported basis but up 19% when adjusted for a customer contract expiration.
• The Pharmaceutical and Specialty Solutions segment was a key driver, with a 14% increase in segment profit due to growth in brand and specialty pharmaceutical sales.
• The company successfully onboarded $10 billion in new customer revenue in FY2025.
• Strategic acquisitions, such as Advanced Diabetes Supply Group, and positive impacts from previous acquisitions like GI Alliance and Integrated Oncology Network, contributed to performance.
• Cardinal Health raised its EPS guidance for the full fiscal year 2025 to a range of $8.05 to $8.15.

In Q4 Fiscal Year 2024, reported on August 14, 2024, the company also reported strong results:

• EPS growth of 29% for both Q4 and the full fiscal year 2024.
• Revenue growth of 12% in Q4 to $59.9 billion, and 11% for fiscal year 2024 to $227 billion.
• Raised FY2025 EPS guidance at that time to $7.55-$7.70.
• Record operating cash flow and adjusted free cash flow in FY2024, reaching $3.8 billion and $3.9 billion, respectively.
• Increased share repurchase expectation to $750 million for FY2025.
• Strategic initiatives included a joint venture with CVS Health called Averon, focusing on biosimilars.

Despite these highlights, challenges have been noted, particularly in the Global Medical Products and Distribution (GMPD) segment due to tariff impacts. The company anticipates gross tariff costs between $200 million and $300 million for FY2026 in this segment. The pharma segment also faced an 8% margin headwind in Q4 FY2024 due to the unwind of a large customer transition.

Implications

The upcoming earnings report for Cardinal Health (NYSE: CAH) will provide critical insights into the company's continued performance and its ability to navigate ongoing market dynamics.

Short-term Implications

The Q4 FY2025 report will confirm whether Cardinal Health can maintain its strong growth trajectory, particularly in its Pharmaceutical and Specialty Solutions segment. Investors will closely watch the actual EPS against the $2.03 forecast and any updates to the full fiscal year 2025 guidance. Positive results could lead to an upward movement in the stock price, while any significant misses or cautious outlooks could trigger a decline. The market will also be keen to see how the company is mitigating the tariff impacts in its GMPD segment and managing the integration of recent acquisitions.

Long-term Outlook

Cardinal Health's long-term outlook hinges on its ability to continue driving growth in its core pharmaceutical distribution business, expand its specialty solutions, and effectively manage supply chain complexities and cost pressures. The success of strategic initiatives, such as the Averon joint venture focused on biosimilars, will be crucial for future revenue streams. The company's capacity to onboard new customers and realize synergies from acquisitions will also play a significant role in its sustained profitability.

Factors That Could Change the Situation

Several factors could influence Cardinal Health's financial performance and, consequently, its stock valuation:

• Tariff Impacts: The ongoing impact of tariffs on the GMPD segment remains a significant challenge. The company's ability to effectively mitigate these costs will be critical.
• Customer Transitions: The unwind of large customer contracts or the successful onboarding of new ones can significantly affect revenue and margins.
• Biosimilar Market Penetration: The pace of biosimilar adoption and the success of initiatives like Averon could provide a substantial growth opportunity.
• Healthcare Spending Trends: Broader trends in healthcare spending, drug pricing, and regulatory changes can impact demand for Cardinal Health's products and services.
• Supply Chain Resilience: The ability to maintain a robust and efficient supply chain in a dynamic global environment is essential for operational stability.
• Inflationary Pressures: Rising operational costs due to inflation could compress margins if not effectively managed.

Summary

Cardinal Health (NYSE: CAH) is scheduled to report its Q4 FY2025 earnings on Tuesday, August 12, 2025, before market open, with an anticipated EPS of $2.03. This report is vital for understanding the company's financial health and future prospects. Recent quarters have shown strong performance, particularly in the Pharmaceutical and Specialty Solutions segment, driven by strategic acquisitions and new customer onboarding. However, challenges such as tariff impacts on the GMPD segment and customer contract transitions remain areas of focus. The upcoming report will provide clarity on how Cardinal Health is navigating these factors and its updated outlook for fiscal year 2026, influencing investor sentiment and the company's long-term trajectory in the healthcare industry.